Successful treatment of Scedosporium aurantiacum osteomyelitis in an immunocompetent patient

Surgical Infections

Volumn 8, Issue 6, 2007, Pages 605-610

  Kooijman, Carolien M ^a,d   Kampinga, Greetje A ^b,d   Sybren De Hoog, G ^c   Goudswaard, Willem B ^a   Reijnen, Michel M P J ^a,e  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b Public Health Service of Northern Friesland   (Netherlands)

^c CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Medical Microbiology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; POLY(HEXAMETHYLENEBIGUANIDE); RIBOSOME DNA; VORICONAZOLE;

ADULT; BELOW KNEE AMPUTATION; CASE REPORT; CONFERENCE PAPER; DEBRIDEMENT; DRUG SUBSTITUTION; FISTULA; HUMAN; IMMUNOCOMPETENCE; LEG INJURY; MALE; MANURE; OSTEOMYELITIS; PHLEGMON; PHOTODERMATOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RASH; SCEDOSPORIUM; SCEDOSPORIUM AURANTIACUM; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT RESPONSE; WOUND INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BIGUANIDES; CELLULITIS; DNA, FUNGAL; DNA, RIBOSOMAL; HUMANS; IMMUNOCOMPROMISED HOST; LEG INJURIES; MALE; MYCOSES; OSTEOMYELITIS; PSEUDOMONAS AERUGINOSA; SCEDOSPORIUM; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS AUREUS;

EID: 37549000925     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.038     Document Type: Conference Paper

References (30)

1. Buxton TB, Travis MT, O'Shea KJ, et al. Low-dose infectivity of Staphylococcus aureus (SMH strain) in traumatized rat tibiae provides a model for studying early events in contaminated bone injuries. Comp Med 2005;55:123-128.
2. Herruzo-Cabrera R, Lopez-Gimenez R, Diez-Sebastian J, et al. Surgical site infection of 7301 traumatologic inpatients (divided in two sub-cohorts, study and validation): Modifiable determinants and potential benefit. Eur J Epidemiol 2004;19:163-169.
3. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-379.
4. Guarro J, Kantarcioglu AS, Horre R, et al. Scedosporium apiospermum: Changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 2006;44:295-327.
5. Steinbach WJ, Schell WA, Miller JL, et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003;41:3981-3985.
6. Studahl M, Backteman T, Stalhammar F, et al. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr 2003;92:980-982.
7. Panackal AA, Marr KA. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 2004;25:171-181.
8. Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole: Case report. J Neurosurg 2005;103:83-87.
9. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: Clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005;40:89-99.
10. Gilgado F, Cano J, Gene J, et al. Molecular phylogeny of the Pseudallescheria boydii species complex: Proposal of two new species. J Clin Microbiol 2005;43:4930-4942.
11. Borman AM, Campbell CK, Linton CJ, et al. Polycytella hominis is a mutated form of Scedosporium apiospermum. Med Mycol 2006;44:33-39.
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A. National Committee for Clinical Laboratory Standards. Wayne, Pennsylvania, 2002.
13. Figueroa MS, Fortun J, Clement A, et al. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina 2004;24:319-320.
14. Reimann D, Bussemaker E, Gross P. Successful treatment due to vacuum seal technique of a severe Scedosporium apiospermum skin infection in a renal transplant recipient. Nephrol Dial Transplant 2004;19:245-248.
15. Bosma F, Voss A, van Hamersvelt HW, et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect 2003;9:750-753.
16. O'Bryan TA, Browne FA, Schonder JF. Scedosporium apiospermum (Pseudallescheria boydii) endocarditis. J Infect 2002;44:189-192.
17. Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000;31:673-677.
18. Pickles RW, Pacey DE, Muir DB, et al. Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy. J Infect 1996;33:193-197.
19. German JW, Kellie SM, Pai MP, et al. Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis: Case report. Neurosurg Focus 2004;17:E9.
20. Hernandez Prats C, Llinares Tello F, Burgos San Jose A, et al. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 2004;38:414-417.
21. Kowacs PA, Soares Silvado CE, Monteiro de Almeida S, et al. Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors. J Clin Pathol 2004;57:205-207.
22. Farina C, Arosio M, Marchesi G, et al. Scedosporium apiospermum post-traumatic cranial infection. Brain Inj 2002;16:627-631.
23. Cimon B, Carrere J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000;19:53-56.
24. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62-68.
25. Howden BP, Slavin MA, Schwarer AP, et al. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003;22:111-113.
26. Donnelly JP, de Pauw BE. Voriconazole: A new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004;10(Suppl 1):107-117.
27. Messick CR, Pendland SL, Moshirfar M, et al. In-vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis. J Antimicrob Chemother 1999;44:297-298.
28. Chang CY, Schell WA, Perfect JR, et al. Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis. Laryngoscope 2005;115:1065-1069.
29. Seal DV. Acanthamoeba keratitis update: Incidence, molecular epidemiology and new drugs for treatment. Eye 2003;17:893-905.
30. Horre R, Feil E, Stangel AP, et al. Scedosporiosis of the brain with fatal outcome after traumatization of the foot: Case report. Mycoses 2000;43(Suppl 2):33-36.